McCance D R, Dyer D G, Dunn J A, Bailie K E, Thorpe S R, Baynes J W, Lyons T J
Sir George E. Clark Metabolic Unit, Royal Victoria Hospital, Belfast, Northern Ireland, United Kingdom.
J Clin Invest. 1993 Jun;91(6):2470-8. doi: 10.1172/JCI116482.
Glycation, oxidation, and browning of proteins have all been implicated in the development of diabetic complications. We measured the initial Amadori adduct, fructoselysine (FL); two Maillard products, N epsilon-(carboxymethyl) lysine (CML) and pentosidine; and fluorescence (excitation = 328 nm, emission = 378 nm) in skin collagen from 39 type 1 diabetic patients (aged 41.5 +/- 15.3 [17-73] yr; duration of diabetes 17.9 +/- 11.5 [0-46] yr, [mean +/- SD, range]). The measurements were related to the presence of background (n = 9) or proliferative (n = 16) retinopathy; early nephropathy (24-h albumin excretion rate [AER24] > or = 20 micrograms/min; n = 9); and limited joint mobility (LJM; n = 20). FL, CML, pentosidine, and fluorescence increased progressively across diabetic retinopathy (P < 0.05, P < 0.001, P < 0.05, P < 0.01, respectively). FL, CML, pentosidine, and fluorescence were also elevated in patients with early nephropathy (P < 0.05, P < 0.001, P < 0.01, P < 0.01, respectively). There was no association with LJM. Controlling for age, sex, and duration of diabetes using logistic regression, FL and CML were independently associated with retinopathy (FL odds ratio (OR) = 1.06, 95% confidence interval (CI) = 1.01-1.12, P < 0.05; CML OR = 6.77, 95% CI = 1.33-34.56, P < 0.05) and with early nephropathy (FL OR = 1.05, 95% CI = 1.01-1.10, P < 0.05; CML OR = 13.44, 95% CI = 2.00-93.30, P < 0.01). The associations between fluorescence and retinopathy and between pentosidine and nephropathy approached significance (P = 0.05). These data show that FL and Maillard products in skin correlate with functional abnormalities in other tissues and suggest that protein glycation and oxidation (glycoxidation) may be implicated in the development of diabetic retinopathy and early nephropathy.
蛋白质的糖基化、氧化和褐变均与糖尿病并发症的发生有关。我们测定了39例1型糖尿病患者(年龄41.5±15.3[17 - 73]岁;糖尿病病程17.9±11.5[0 - 46]年,[均值±标准差,范围])皮肤胶原蛋白中的初始阿马多里加合物果糖赖氨酸(FL);两种美拉德产物,Nε-(羧甲基)赖氨酸(CML)和戊糖苷;以及荧光(激发波长 = 328 nm,发射波长 = 378 nm)。这些测量结果与背景性(n = 9)或增殖性(n = 16)视网膜病变的存在;早期肾病(24小时白蛋白排泄率[AER24]≥20微克/分钟;n = 9);以及关节活动受限(LJM;n = 20)相关。FL、CML、戊糖苷和荧光在糖尿病视网膜病变患者中逐渐升高(分别为P < 0.05、P < 0.001、P < 0.05、P < 0.01)。FL、CML、戊糖苷和荧光在早期肾病患者中也升高(分别为P < 0.05、P < 0.001、P < 0.01、P < 0.01)。与LJM无关联。使用逻辑回归控制年龄、性别和糖尿病病程后,FL和CML与视网膜病变独立相关(FL比值比(OR) = 1.06,95%置信区间(CI) = 1.01 - 1.12,P < 0.05;CML OR = 6.77,95% CI = 1.33 - 34.56,P < 0.05),与早期肾病也独立相关(FL OR = 1.05,95% CI = 1.01 - 1.10,P < 0.05;CML OR = 13.44,95% CI = 2.00 - 93.30,P < 0.01)。荧光与视网膜病变之间以及戊糖苷与肾病之间的关联接近显著水平(P = 0.05)。这些数据表明,皮肤中的FL和美拉德产物与其他组织的功能异常相关,并提示蛋白质糖基化和氧化(糖氧化)可能与糖尿病视网膜病变和早期肾病的发生有关。